Edwards Lifesciences Corp
Research Edwards Lifesciences Corp (EW) on Bullrun: valuation model: 24.4% overvalued, market cap USD 49.13B, P/E 50.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEW
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal24.4% overvalued
- Market capUSD 49.13B
- P/E50.6
- Financial periodQ2 2026
- RevenueUSD 1.74B
- Net incomeUSD 241.90M
- Free cash flowUSD 585.00M
- Gross margin77.5%
Valuation Snapshot
Bullrun's latest valuation model marks Edwards Lifesciences Corp as 24.4% overvalued; latest market cap is USD 49.13B; P/E is 50.6.
Peer valuation comparison
Latest P/E is 50.56x versus a Healthcare sector median of 24.61x (105.5% above).
Latest P/E is 50.56x versus a United States median of 23.85x (112.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.07B | USD 1.07B | USD 1.34B | 78.0% | 1.83 | USD 2.94B | USD 598.30M | USD 10.34B |
| FY2024 | USD 5.44B | USD 4.17B | USD 289.90M | 79.5% | 6.97 | USD 3.05B | USD 597.70M | USD 10.00B |
| FY2023 | USD 5.01B | USD 1.40B | USD 642.80M | 80.5% | 2.3 | USD 1.13B | USD 597.00M | USD 6.65B |
| FY2022 | USD 4.46B | USD 1.52B | USD 973.60M | 83.8% | 2.44 | USD 769.00M | USD 596.30M | USD 5.81B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 49.13B | 50.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 49.50B | 47.1 | n/a | n/a |
| 2024 | 2024-12-31 | USD 43.57B | 10.6 | n/a | n/a |
| 2023 | 2023-12-29 | USD 46.25B | 32.6 | n/a | n/a |
| 2022 | 2022-12-30 | USD 46.13B | 32.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 80.85B | 54.4 | n/a | n/a |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
ETFs that hold Edwards Lifesciences Corp
Edwards Lifesciences Corp is one of the ten largest holdings of 3 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| iShares US Medical Devices UCITS ETF USD (Acc) | 5.16% | 0.25% |
| VanEck Medical Robotics and Bionic Engineering UCITS ETF | 9.66% | 0.55% |
| Ossiam US Minimum Variance ESG NR UCITS ETF 1A (USD) | 3.95% | 0.65% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Edwards Lifesciences Corp overvalued or undervalued?
Bullrun's valuation model currently marks Edwards Lifesciences Corp as 24.4% overvalued.
What is Edwards Lifesciences Corp's market cap?
Edwards Lifesciences Corp's market capitalization is USD 49.13B.
What is Edwards Lifesciences Corp's P/E ratio?
Edwards Lifesciences Corp's price-to-earnings (P/E) ratio is 50.6.
What does Edwards Lifesciences Corp do?
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.